Lantheus Holdings, Inc. (LNTH)
- Previous Close
65.21 - Open
63.02 - Bid 65.19 x 100
- Ask 65.26 x 100
- Day's Range
63.76 - 65.27 - 52 Week Range
50.20 - 100.85 - Volume
602,997 - Avg. Volume
860,151 - Market Cap (intraday)
4.47B - Beta (5Y Monthly) 0.54
- PE Ratio (TTM)
14.02 - EPS (TTM)
4.65 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
97.50
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
www.lantheus.com834
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: LNTH
Performance Overview: LNTH
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LNTH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LNTH
Valuation Measures
Market Cap
4.47B
Enterprise Value
4.37B
Trailing P/E
14.02
Forward P/E
9.92
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.53
Price/Book (mrq)
5.48
Enterprise Value/Revenue
3.37
Enterprise Value/EBITDA
8.91
Financial Highlights
Profitability and Income Statement
Profit Margin
25.20%
Return on Assets (ttm)
21.28%
Return on Equity (ttm)
51.73%
Revenue (ttm)
1.3B
Net Income Avi to Common (ttm)
326.66M
Diluted EPS (ttm)
4.65
Balance Sheet and Cash Flow
Total Cash (mrq)
713.66M
Total Debt/Equity (mrq)
75.85%
Levered Free Cash Flow (ttm)
155.91M
Research Analysis: LNTH
Company Insights: LNTH
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: LNTH
LNTH: Raising target price to $68.00
LANTHEUS HOLDINGS INC has an Investment Rating of HOLD; a target price of $68.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLNTH: Raising target price to $65.00
LANTHEUS HOLDINGS INC has an Investment Rating of HOLD; a target price of $65.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLNTH: Raising target price to $63.00
LANTHEUS HOLDINGS INC has an Investment Rating of HOLD; a target price of $63.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLNTH: What does Argus have to say about LNTH?
LANTHEUS HOLDINGS INC has an Investment Rating of HOLD; a target price of $62.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target